secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001140361-23-028066
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma reduces stockholder meeting quorum requirement from majority to one-third
--------------------------------------------------------------------------------

- Board approved amendment to Bylaws reducing quorum for stockholder meetings from a majority to one-third of voting power, effective June 1, 2023.
- Amendment modifies Section 8 of Article III of the Second Amended and Restated Bylaws.
- No changes to fiscal year or other provisions of the Bylaws.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123028066/0001140361-23-028066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123028066/brhc20053954_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-028066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer